covid_cell_1

Pharmafile.com’s weekly COVID-19 news round-up

pharmafile | August 5, 2020 | News story | Research and Development COVID-19, Weekly round up, coronavirus 

The coronavirus news this week is dominated by vaccine development, as the UK Government sealed another deal to procure an effective vaccine for its citizens, partnering up with Sanofi and GlaxoSmithKline to reserve 60 million doses of their potential prophylactic candidate currently in development, while the EU has reached an agreement with Sanofi for 300 million doses of their COVID-19 vaccine candidate. 

In other COVID-19 news, two new coronavirus tests are set to be made available throughout England that are significantly faster than most already in use.

UK Government secures 60 million doses of Sanofi and GSK’s COVID-19 vaccinePublished on 29/07/20

The UK Government has sealed another deal to procure an effective COVID-19 vaccine for its citizens, partnering up with Sanofi and GlaxoSmithKline to reserve 60 million doses of their potential prophylactic candidate currently in development.

England to start using two new 90-minute COVID-19 tests in preparation for the winterPublished on 03/08/20

Two new coronavirus tests are set to be made available throughout England that are significantly faster than most already in use.

EU agrees deal with Sanofi for COVID-19 vaccine supplyPublished on 03/08/20

The EU has reached an agreement with Sanofi for 300 million doses of their COVID-19 vaccine candidate which will allow the trading bloc’s members to purchase the vaccines if and when it gets an approval.

US Government commits $2.1bn to GSK and Sanofi’s COVID-19 vaccine candidatePublished on 03/08/20

The US Government has announced additional funding into Sanofi and GlaxSmithKline’s efforts to develop a recombinant protein-based vaccine to the value of $2.1 billion, as part of its Operation Warp Speed to identify, fund and deliver an effective COVID-19 vaccine from a range of promising candidates.

Yale-backed study to test efficacy of AI-selected therapy in COVID-19Published on 28/07/20

Biopharma firm AI Therapeutics is partnering with Yale School of Medicine to launch a new clinical trial to identify the efficacy of a drug selected using artificial intelligence (AI) in the treatment of COVID-19 infection.

Conor Kavanagh

Related Content

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …

moderna_norwood_plant

Moderna and Pfizer COVID-19 vaccine protection declines over time

Data presented by Pfizer and Moderna ahead of the FDA’s vaccine advisory committee meeting on …

Sanofi complete acquisition of mRNA company Translate Bio

French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal …

Latest content